Liquidia swings to $74.7M profit on 1843% revenue surge to $171.7M as YUTREPIA ramps

Filed August 12, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 12, 2025 · ~2 min read

Key Changes

• high

  Revenue surged 1842.7% YoY to $171.7M in Q2 2026 (vs $8.8M prior year), driven by YUTREPIA's first full year of commercial sales following May 2025 FDA approval; product sales reached $170.4M in the quarter.

  MD&A: Revenue verify on EDGAR →
• high

  Net income swung from a $41.6M loss in Q2 2025 to $74.7M profit in Q2 2026; operating income turned positive at $85.5M (vs -$37.5M loss prior year), marking the company's first profitable period.

  MD&A: Profitability verify on EDGAR →
• high

  Operating cash flow swung from a $70.2M use to a $133.2M source for the six months ended June 30, 2026; cash position strengthened to $284.2M (vs $173.4M prior year) as the company repaid $28M in HCR debt.

  MD&A: Cash Flow verify on EDGAR →